caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a positive allosteric modulator, a npy y5 antagonist, and a kinase inhibitor, belonging to both the diabetes treatment and anti obesity classes, and is gpr119 modulator. | CC(=N)C1CCC(C)CC1 | [
"diabetes treatment",
"positive allosteric modulator",
"anti obesity",
"gpr119 modulator",
"npy y5 antagonist",
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting metabolic syndrome. The molecule is a nutrient that impacts cardiovascular disease, atherosclerosis, and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC | [
"Thyroxine treatment",
"Metabolic syndrome",
"Fat storage",
"Cardiovascular disease",
"Atherosclerosis",
"nutrient",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti bacterial class of molecules. | N#CCc1c(F)cc(Br)c([N+](=O)[O-])c1F | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, membrane stabilizer, nutrient, energy storage that impacts cancer and atherosclerosis. The molecule is a inflammatory that impacts both metabolic syndrome and pancreatitis. The molecule is a fat storage and a thyroxine treatment, impacting both cardiovascular disease and obesity. | CCC(C)CCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C | [
"Energy source",
"Cancer",
"Membrane stabilizer",
"Atherosclerosis",
"nutrient",
"Energy storage",
"inflammatory",
"Metabolic syndrome",
"Pancreatitis",
"Cardiovascular disease",
"Obesity",
"Fat storage",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory that impacts obesity, cancer, cardiovascular disease, pancreatitis, and metabolic syndrome. The molecule is a nutrient, a membrane stabilizer, and a energy storage. The molecule is a fat storage and a energy source, impacting both atherosclerosis and thyroxine treatment. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Obesity",
"Cancer",
"inflammatory",
"Cardiovascular disease",
"Pancreatitis",
"Metabolic syndrome",
"nutrient",
"Membrane stabilizer",
"Energy storage",
"Fat storage",
"Energy source",
"Atherosclerosis",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hiv protease inhibitor. | CNCc1cc(OC)c(OC)cc1-c1sc2c(c1C(=O)O)CC(C)(C)CC2 | [
"hiv protease inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier and a energy source, impacting both barth syndrome and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, membrane stabilizer, energy storage, food additive, proton trap for oxidative phosphorylation. The molecule is a stabilizing cytochrome oxidase, a nutrition... | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C=C/CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Barth syndrome",
"Emulsifier",
"Energy source",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Membrane stabilizer",
"Energy storage",
"food additive",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Nutritional supplement",
"Stabilizing mit... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a diabetes treatment and is anti diabetic. | Cc1cc2c(cn1)c(=O)cc(S(=O)CC1CCCCC1)n2-c1ccccc1 | [
"anti diabetic",
"diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammation treatment member of the cancer treatment class. | CC1C=Cc2oc3nc(=O)[nH]c(=O)c-3cc2C1 | [
"inflammation treatment",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti viral, hcv treatment, and anti viral activity compound. | CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)N(c4ccccn4)C4CC4)c(OCC(N)=O)cc3C)cc12 | [
"anti viral",
"hcv treatment",
"anti viral activity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts tangier disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule has Odorless. When heated to decomposition it emits acrid smoke and irritating fumes. | C=C(C)C1Cc2c(ccc3c2OC2COc4cc(OC)c(OC)cc4C2C3=O)O1 | [
"Odor_evaluation",
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and barth syndrome. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts non-alcoholic fatty liver disease, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is inflammation treatment. | CCOC(=O)CCc1cc(-c2ccccc2)ccc1OCCCOc1cc(O)c(C(C)=O)cc1CC | [
"inflammation treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, alzheimer's disease, and diabetes mellitus type 2. | CCCCCC/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC/C=C\C/C=C\C/C=C\C=C\[C@@H](O)CCCCC | [
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts aging, non-alcoholic fatty liver disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC | [
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and nutrient, and it impacts thyroxine treatment. It impacts metabolic syndrome, atherosclerosis, cardiovascular disease, and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Fat storage",
"Thyroxine treatment",
"nutrient",
"Metabolic syndrome",
"Atherosclerosis",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\C=C/C(O)C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor and is cancer treatment. | CC1CC(NC(=O)OC(C)(C)C)CC(c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)ccc(C=O)c3F)n2)C1 | [
"kinase inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomposition it emits very toxic fumes of chlorides, nitrogen oxides, and cyanides. The molecule has Pungent odor. | N#CCCl | [
"Decomposition_evaluation",
"Odor_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, fat storage, inflammatory that has an effect on cancer and impacts cardiovascular disease. The molecule is a nutrient and thyroxine treatment, and it impacts atherosclerosis. The molecule is a energy storage that impacts obesity, pancreatitis, and metabolic syndrome... | CCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC)COC(=O)CCCCCCCCCCCCC(C)C | [
"Membrane stabilizer",
"Cardiovascular disease",
"Cancer",
"Energy source",
"Fat storage",
"inflammatory",
"Thyroxine treatment",
"nutrient",
"Atherosclerosis",
"Obesity",
"Pancreatitis",
"Energy storage",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti hypertensive. | CC1(C)C=C(n2cc(Br)cc([N+](=O)[O-])c2=O)c2cccnc2O1 | [
"anti hypertensive"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is diabetes treatment. | CCCCOc1ccc(CC(N)C2=NC(C=C(C)C=C(C)C(=O)OCC)CS2)cc1 | [
"diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a cholesterol translocation and a apoptosis that impacts tangier disease, aging, and barth syndrome. | CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both metabolic syndrome and atherosclerosis. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both cardiovascular disease and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Metabolic syndrome",
"Atherosclerosis",
"nutrient",
"Fat storage",
"Cardiovascular disease",
"Thyroxine treatment",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, energy storage, nutrient, membrane stabilizer that has an effect on cancer and impacts atherosclerosis. It impacts obesity, metabolic syndrome, and pancreatitis. The molecule is a inflammatory and energy source, belonging to the thyroxine treatment class of molecules, and impacts cardiova... | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)CC | [
"Fat storage",
"Energy storage",
"nutrient",
"Cancer",
"Membrane stabilizer",
"Atherosclerosis",
"Obesity",
"Metabolic syndrome",
"Pancreatitis",
"inflammatory",
"Thyroxine treatment",
"Energy source",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both cardiovascular disease and metabolic syndrome. The molecule is a fat storage and thyroxine treatment, impacting both pancreatitis and atherosclerosis. | CCCCCCCC/C=C\CCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCCCC | [
"Cardiovascular disease",
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Fat storage",
"Thyroxine treatment",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts thyroxine treatment, cardiovascular disease, and metabolic syndrome. The molecule is a nutrient and a fat storage, impacting both atherosclerosis and pancreatitis. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Thyroxine treatment",
"Cardiovascular disease",
"Metabolic syndrome",
"Atherosclerosis",
"nutrient",
"Fat storage",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, aging, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease. The molecule is a cholesterol translocation that impacts barth syndrome, non-alcoholic fatty liver disease, aging, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is cancer treatment. | CN(C)C1CCN(c2ccc3c(c2)CC(CN)(c2cccc(-c4ncnc5[nH]ccc45)c2)C3)C1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a immunomodulator and belongs to both the cb2 agonist and inflammation treatment classes of molecules. | CC(C)(C)c1cc(NC(=O)C(C)(C)S(=O)(=O)c2ccc(C(F)(F)F)nc2)n[nH]1 | [
"cb2 agonist",
"immunomodulator",
"inflammation treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts barth syndrome and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, apoptosis, food additive, proton trap for oxidative phosphorylation. The molecule is a emulsifier, energy source, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a stabilizing mitochondrial structure and smoot... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Cholesterol translocation",
"Apoptosis",
"food additive",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Emulsifier",
"Energy source",
"Stabilizing cytochrome oxidase",
"Smooth",
"Stabilizing mitochondrial structure",
"Aging",
"Tangier d... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a pim kinase inhibitor, a kinase inhibitor, and cancer treatment. | CC(C)(C)OC(=O)NC1CCCN(c2ccccc2[N+](=O)[O-])C1.O=C1C2=CC=C1C=C2 | [
"cancer treatment",
"pim kinase inhibitor",
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage, energy source, inflammatory, energy storage that impacts cancer and atherosclerosis. The molecule is a nutrient that impacts both pancreatitis and metabolic syndrome. The molecule is a membrane stabilizer and thyroxine treatment, impacting both obesity and cardiovascular disease. | CC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Fat storage",
"Energy source",
"Cancer",
"inflammatory",
"Atherosclerosis",
"Energy storage",
"Pancreatitis",
"Metabolic syndrome",
"nutrient",
"Membrane stabilizer",
"Obesity",
"Cardiovascular disease",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts aging. The molecule is a apoptosis that impacts barth syndrome, tangier disease, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti retroviral class of molecules. | CC(C)C(NC(=O)OC(C)C1CCCCN1)C(=O)O | [
"anti retroviral"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and nutrient, and it impacts atherosclerosis. It impacts cardiovascular disease, thyroxine treatment, pancreatitis, and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCC | [
"Fat storage",
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Thyroxine treatment",
"Pancreatitis",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts diabetes treatment. | CCCCCS(=O)(=O)NC(=O)C=Cc1c(Cl)nc(C)n1Cc1ccc(Cl)cc1Cl | [
"diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and tangier disease. | CCC(C)CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a cholesterol translocation and a apoptosis that impacts barth syndrome, aging, and tangier disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Tangier disease",
"Cholesterol translocation",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts barth syndrome and tangier disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Apoptosis",
"Barth syndrome",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, signalling molecule, surfactant, membrane stabilizer, emulsifier, energy storage. | CC(=O)c1ccc(C)cc1C | [
"Energy source",
"signalling molecule",
"surfactant",
"Membrane stabilizer",
"Emulsifier",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a bace1 inhibitor and belongs to the alzheimer's treatment class of molecules. | CN=S1(=O)CC(C)(c2cc(-c3cc(-c4cnc(OC)cn4)no3)ccc2F)N=C(NC(=O)O)C1(C)C | [
"alzheimer's treatment",
"bace1 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti bacterial. | NC1CCCC1SC1OC(CO)C(O)C(O)C1O | [
"anti bacterial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti depressant. | Cc1ccc2c(c1)C1CC(O)C3CCCCC3N1CC2 | [
"anti depressant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects both breast cancer and cervical cancer, and also impacts atherosclerosis and ulcerative colitis. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC | [
"Atherosclerosis",
"nutrient",
"Ulcerative colitis",
"Breast cancer",
"Cervical cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts insulin resistance. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](O)COC(=O)CCCCCCCCCCCCCCCCCCC | [
"Insulin resistance"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts cervical cancer, atherosclerosis, ulcerative colitis, and breast cancer. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCC[C@H]1[C@@H](O)CC(=O)[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)([O-])OCC[N+](C)(C)C | [
"Cervical cancer",
"Atherosclerosis",
"nutrient",
"Ulcerative colitis",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C[C@H]1C(=O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, diabetes mellitus type 2, and alzheimer's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC/C=C/C/C=C\C[C@@H](O)/C=C\C=C/CCCCC | [
"Parkinson's disease",
"nutrient",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is cancer treatment. | CNC(=O)c1ccc(Nc2ncnc3cc(OC)c(NC(=O)C4CCCN4C(=O)C(NCC(C)NC)C(C)(C)C)cc23)cc1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, aging, and barth syndrome. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Aging",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a thyroxine treatment that impacts both pancreatitis and atherosclerosis. The molecule is a fat storage and a nutrient, impacting both metabolic syndrome and cardiovascular disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC(COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Pancreatitis",
"Thyroxine treatment",
"Atherosclerosis",
"Fat storage",
"Metabolic syndrome",
"Cardiovascular disease",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a fluorescent and a fluorescent dye. | CCCC[N+]1=C(C=CC=C2N(CCCS(=O)(=O)O)c3ccc4ccc(S(=O)(=O)O)cc4c3C2(C)CCCS(=O)(=O)O)C(C)(C)c2c1ccc1c(S(=O)(=O)O)cc(S(=O)(=O)O)cc21 | [
"fluorescent",
"fluorescent dye"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and diabetic heart disease. | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is obesity treatment and it impacts diabetes treatment. | O=C1CCC(C=C(c2ccc(S(=O)(=O)C3CC3)cc2)c2ccc(C(F)(F)F)c(=O)[nH]2)C1 | [
"obesity treatment",
"diabetes treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and fat storage, and it impacts metabolic syndrome. It impacts thyroxine treatment, atherosclerosis, cardiovascular disease, and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Metabolic syndrome",
"nutrient",
"Fat storage",
"Thyroxine treatment",
"Atherosclerosis",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a member of the thyroxine treatment class and affects both atherosclerosis and pancreatitis. The molecule is a nutrient and a fat storage, impacting both metabolic syndrome and cardiovascular disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCCCCC | [
"Atherosclerosis",
"Pancreatitis",
"Thyroxine treatment",
"nutrient",
"Fat storage",
"Metabolic syndrome",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts aging. The molecule is a cholesterol translocation that impacts tangier disease, diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on colorectal cancer, and impacts breast cancer, parkinson's disease, and alzheimer's disease. It impacts seizure, diabetes mellitus, stomach cancer, and cardiovascular disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCC[C@H](C)O | [
"Breast cancer",
"Colorectal cancer",
"Parkinson's disease",
"Alzheimer's Disease",
"Seizure",
"Diabetes mellitus",
"Stomach cancer",
"Cardiovascular disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, a membrane stabilizer, and a emulsifier. The molecule is a energy storage, surfactant, signalling molecule, nutrient. | CCCCCCCCCCCCCCC/C=C/C(=O)CC(O)COC(C)=O | [
"Energy source",
"Membrane stabilizer",
"Emulsifier",
"Energy storage",
"surfactant",
"signalling molecule",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts aging and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, nutrient, inflammatory that impacts metabolic syndrome, cancer, and atherosclerosis. The molecule is a membrane stabilizer and belongs to the thyroxine treatment class of molecules, impacting cardiovascular disease. The molecule is a energy storage and a fat storage, impacting both obes... | CCC(C)CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Energy source",
"nutrient",
"Metabolic syndrome",
"inflammatory",
"Cancer",
"Atherosclerosis",
"Thyroxine treatment",
"Membrane stabilizer",
"Cardiovascular disease",
"Energy storage",
"Obesity",
"Fat storage",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage and thyroxine treatment, and it impacts pancreatitis. The molecule is a nutrient that impacts metabolic syndrome, cardiovascular disease, and atherosclerosis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Thyroxine treatment",
"Fat storage",
"Pancreatitis",
"Metabolic syndrome",
"Cardiovascular disease",
"nutrient",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory and energy storage, belonging to the thyroxine treatment class of molecules, and impacts obesity, atherosclerosis, and pancreatitis. The molecule is a nutrient, a energy source, and a fat storage. The molecule is a membrane stabilizer that impacts metabolic syndrome, cardiovascular diseas... | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCC | [
"Obesity",
"inflammatory",
"Energy storage",
"Atherosclerosis",
"Thyroxine treatment",
"Pancreatitis",
"nutrient",
"Energy source",
"Fat storage",
"Metabolic syndrome",
"Cardiovascular disease",
"Membrane stabilizer",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts ulcerative colitis, breast cancer, cervical cancer, and atherosclerosis. | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CC[C@@H](O)CC)COP(=O)([O-])OCC[N+](C)(C)C | [
"Ulcerative colitis",
"Breast cancer",
"nutrient",
"Cervical cancer",
"Atherosclerosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a cholesterol translocation that impacts non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts aging and barth syndrome. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Aging",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts seizure, cardiovascular disease, parkinson's disease, and diabetes mellitus. It has an effect on stomach cancer, and impacts breast cancer, alzheimer's disease, and colorectal cancer. | CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O | [
"Seizure",
"Cardiovascular disease",
"Parkinson's disease",
"Diabetes mellitus",
"Breast cancer",
"Stomach cancer",
"Alzheimer's Disease",
"Colorectal cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts tangier disease, non-alcoholic fatty liver disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti tumor activity. | CC(C)C1=C(C(=O)N2C(C)CCC2C(=O)N2CCN(CCO)C(C)(C)C2)SC2=NC(C)(c3ccc(Cl)cc3)C(c3ccc(Cl)cc3)N21 | [
"anti tumor activity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts alzheimer's disease, diabetes mellitus, and stomach cancer. It has an effect on colorectal cancer, and impacts parkinson's disease, seizure, and cardiovascular disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCC[C@@H](O)[C@H](O)/C=C\C=C/C=C/C=C/[C@@H](O)C/C=C\CC | [
"Breast cancer",
"Alzheimer's Disease",
"Diabetes mellitus",
"Stomach cancer",
"Parkinson's disease",
"Seizure",
"Cardiovascular disease",
"Colorectal cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts tangier disease, non-alcoholic fatty liver disease, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, inflammatory, fat storage, energy storage that has an effect on cancer and impacts metabolic syndrome. The molecule is a thyroxine treatment and energy source, and it impacts obesity. The molecule is a nutrient that impacts atherosclerosis, cardiovascular disease, and pancreatitis... | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Membrane stabilizer",
"Metabolic syndrome",
"inflammatory",
"Fat storage",
"Energy storage",
"Cancer",
"Thyroxine treatment",
"Energy source",
"Obesity",
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts diabetes mellitus, seizure, parkinson's disease, and colorectal cancer. It has an effect on breast cancer, and impacts alzheimer's disease, cardiovascular disease, and stomach cancer. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCCCCCC[C@H](O)[C@@H](O)C/C=C\CCCCC | [
"Diabetes mellitus",
"Seizure",
"Parkinson's disease",
"Colorectal cancer",
"Alzheimer's Disease",
"Breast cancer",
"Cardiovascular disease",
"Stomach cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a 11beta-hsd1 inhibitor and is metabolic disease treatment. | O=C(O)CC1(Cc2ccccc2Cl)C2CC3CC(C2)CC1C3 | [
"11beta-hsd1 inhibitor",
"metabolic disease treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
When heated to decomp it emits very toxic fumes of nitrogen oxides and organic fumes. | CN1CCCC1c1cccnc1.CN1CCCC1c1cccnc1.O=S(=O)(O)O | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts barth syndrome and tangier disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts aging, non-alcoholic fatty liver disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts alzheimer's disease, parkinson's disease, colorectal cancer, and stomach cancer. It impacts breast cancer, diabetes mellitus, cardiovascular disease, and seizure. | CC/C=C\C[C@@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)/C=C\CCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Alzheimer's Disease",
"Parkinson's disease",
"Colorectal cancer",
"Stomach cancer",
"Breast cancer",
"Diabetes mellitus",
"Cardiovascular disease",
"Seizure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a egfr inhibitor. | C=CC(=O)Nc1cc(Nc2cn3c(C4CC4)cnc3cn2)c(OC)cc1N1CCC(N(C)C)CC1 | [
"egfr inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts aging. The molecule is a stabilizing mitochondrial structure that impacts diabetic heart disease, barth syndrome, non-alcoholic fatty liver disease, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts barth syndrome. The molecule is a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, aging, tangier disease, and diabetic heart disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts barth syndrome, tangier disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the s1p1 agonist class of molecules. | CCOc1cccc(Oc2ccc(NC(=O)C(C)(N)CO)cc2)c1 | [
"s1p1 agonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Decomposes at melting point. | [Cu+2].[O-][As]([O-])O | [
"Decomposition_evaluation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both cardiovascular disease and atherosclerosis. The molecule is a nutrient that impacts metabolic syndrome, pancreatitis, and thyroxine treatment. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Cardiovascular disease",
"Atherosclerosis",
"Fat storage",
"nutrient",
"Metabolic syndrome",
"Pancreatitis",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts barth syndrome and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Apoptosis",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor. | CC(C)(O)c1ccc2c(c1)[nH]c1c(C(N)=O)cc(Cl)c(-c3cccc(-n4c(=O)[nH]c5c(F)cc(F)cc5c4=O)c3)c12 | [
"kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both pancreatitis and cardiovascular disease. The molecule is a fat storage and belongs to the thyroxine treatment class of molecules, impacting both atherosclerosis and metabolic syndrome. | CCCC/C=C\CCCCCCCC(=O)O[C@H](COCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Pancreatitis",
"nutrient",
"Cardiovascular disease",
"Atherosclerosis",
"Thyroxine treatment",
"Fat storage",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, barth syndrome, and diabetic heart disease. | CCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Aging",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, sulfury, alliaceous, and roasted. The molecule is a flavoring agent, coffee, smoke, meaty, fishy. | C=C(C=O)[C@@H]1CC[C@]2(C)[C@H]3CCC4[C@@]5(C)CC[C@H](O)C(C)(C)C5CC[C@@]4(C)[C@]3(C)CC[C@@H]12 | [
"sulfury",
"alliaceous",
"roasted",
"nutrient",
"coffee",
"smoke",
"meaty",
"fishy",
"Flavoring agent"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a tyrosine kinase inhibitor and a protein kinase inhibitor. | COc1ccc2c(c1)-c1nc(Nc3ccc(OC)c(OCCN(C)C)c3)ncc1CC2(C)C | [
"tyrosine kinase inhibitor",
"protein kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts tangier disease. The molecule is a stabilizing cytochrome oxidase that impacts diabetic heart disease, barth syndrome, non-alcoholic fatty liver disease, and aging. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, surfactant, energy source, emulsifier, energy storage, nutrient. | C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O[C@H]4CC[C@@]5(C)[C@@H](CC[C@]6(C)[C@@H]5CC=C5[C@@H]7CC(C)(C)C[C@@H](O)[C@]7(C)CC[C@]56C)[C@@]4(C)CO)O[C@H](C(=O)O)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O | [
"Membrane stabilizer",
"surfactant",
"Energy source",
"Emulsifier",
"Energy storage",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fibrosis treatment and is inflammatory disease treatment. | Cc1noc(-c2ccccc2-c2ccc(C3(C(=O)O)CC3)cc2)c1Nc1cncc(-c2ccccc2)c1 | [
"fibrosis treatment",
"inflammatory disease treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.